顺尔宁治疗和预防98例儿童咳嗽变异性哮喘的疗效观察

目的:探讨顺尔宁(孟鲁司特钠)治疗及预防儿童咳嗽变异性哮喘的疗效。方法:对98例咳嗽变异性哮喘(cough variant asthm a,CVA)患儿,按2∶1比例随机分成治疗组65例和对照组33例。对照组接受博利康尼加酮替酚口服治疗,至症状、体征消失后停药,结束后随访12个月转变成典型哮喘的比例。治疗组在对照组治疗基础上加用孟鲁司特钠,至症状、体征消失后停用博利康尼加酮替酚,继续服用孟鲁司特钠,总疗程12周,停药后再随访12个月转化成典型哮喘的比例。对于2~12岁的32例患儿,于治疗前和治疗后3个月,均给予FEV1和PEF测定,比较两组患儿治疗前后肺功能变化情况。结果:治疗组取得临床缓解所需时间(T)比对照组明显缩短,且典型哮喘转化率均较对照组明显降低;用药3个月,治疗组肺功能较治疗前明显改善(P<0.01)。结论:顺尔宁(孟鲁司特钠)治疗及预防咳嗽变异性哮喘疗效肯定,副作用少,患者依从性好。

Observing the effect of montelukast on 98 children with cough variant asthma

Objective:To study curative effect of Montelukast in children with cough variant asthma(CVA).Methods:98 children with CVA were assigned to two groups in the ratio of 2∶1.65 cases were in the study-group and the others belonging to the control group.The control group was treated with-Terbutaline and Ketotifen.The treatment withdraw until the symptom disappeared,the recurrence rate of CVA was investigated at the follow-up of 12 months.The study group was treated with Montelukast besides Terbutaline and Ketotifen were with drawn until the symptom disappeared,however,Montelukast was still taken till the course of treatment reached 12 weeks.The incidence of CVA recurrence rate was also investigated at the follow-up of 12 months.For 32 children who were 2~12 year old,the FEV 1 and PEF were measured before treatment and 12 weeks after treatment.Results:The remission time of study group was shorter than the control group;the recurrence rate and incidence of CVA-Asthma convention were lower.Lung function in study group improved significantly compared to the control group after 12 weeks-treatment(P<0.01).Conclusion:The curative effect of Montelukast in children with CVA is significant,with little side effect and good obedience.